REVOLUTION MEDICINES, INC.
Last · NasdaqGS$189.26-4.26 (-2.20%)live · yahoo · 1h ago
Market cap$40.57B214.3M sh
P/E · TTM-21.3fwd -32.5 · eps -8.87 · loss
Beta—vs S&P 500
Div yield0.00%annual · TTM
52w range
$49.05$224.31
Volume1.5Msession
| Revenue | $29.5M |
|---|---|
| Operating income | $-184.0M |
| Net income | $-166.4M |
| Free cash flow | $-132.4M |
| Operating margin | -623.1% |
| Net margin | -563.6% |
| Return on equity | -17.9% |
| Period | TTM 2023-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-02-25
- Clinical Stage Biotech
- Ras On Inhibitors
- Breakthrough Therapy Designations
- Cash Burn
- Equity Dilution
- Secured Debt
- Patent Risk
Red flags
- Net loss increased to $1.131 billion in 2025 from $600.1 million in 2024, while R&D expense rose $395.1 million to $987.3 million and G&A expense rose $97.7 million to $195.0 million.
- The company has never generated product revenue, has incurred losses every year since inception, and reported a $2.9 billion accumulated deficit as of December 31, 2025.
- Share-based financing is material: 6.16 million shares were sold through the 2024 ATM for $347.9 million net in 2025; weighted-average shares rose to 190.1 million from 167.7 million in 2024, with 24.5 million potentially dilutive securities outstanding at year-end.
- The company has a secured term-loan facility of up to $750.0 million, bearing interest at three-month SOFR plus 5.75% and secured by substantially all assets; drawing the first $250.0 million is tied to FDA approval for daraxonrasib in metastatic PDAC.
- Management says existing cash, cash equivalents and marketable securities fund planned operations for at least 12 months, but additional financing may be required and may be unavailable or dilutive.
Upcoming earnings
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
−$2.39
Est. revenue
23.3M
Earnings transcripts
Press & signals
- GlobeNewswire
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress